Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Famitinib in Advanced Solid Tumor
NCT04346381Phase 2Completed
- Sponsor
- Hengrui
- Start
- Jun 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, famitinib in solid tumor, sponsored by Hengrui. Started Jun 2020; status: completed.
02
Drugs
camrelizumabfamitinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04346381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04346381.